ClinicalTrials.gg
TerminatedNCT01859637Updated Mar 28, 2016Results posted

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

A Phase 4 interventional study of Filgrastim in Severe Chronic Neutropenia, sponsored by Sandoz. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was terminated
Additional pharmacovigilance activity was considered as fulfilled by the EMA.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Purpose of the study is to investigate the safety, immunogenicity and the efficacy of Zarzio®/Filgrastim HEXAL® under chronic administration for 12 months in patients diagnosed with severe chronic neutropenia.

Read the detailed description

This was a prospective, open-label, non-comparative study. Eligible patients with Severe Chronic Neutropenia received Zarzio® for 12 months. Study visits were scheduled for screening, start of treatment with Zarzio®/Filgrastim HEXAL®, 6 weeks after start of treatment and at months 3, 6, 9 and 12.

Immunogenicity assessment: Patients were screened for anti-recombinant human granulocyte colony stimulating factor (rhG-CSF) antibodies at screening (Visit 01) and at every study visit with the exception of Visit 02 (start of treatment). The evaluation of the immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP). Samples positive for binding antibodies in the confirmatory RIP assay were evaluated for neutralizing antibodies using a validated cell-based neutralization antibody assay (NAB).

Efficacy: Complete blood counts with differential white blood cell counts were performed and absolute neutrophil count (ANC) were calculated at every study visit. For each time point the neutrophil counts are summarized by the SAF set using descriptive statistics for the ANC as well as for the changes from baseline.

Safety: Adverse events are listed for the safety population set (SAF) (term, date of AE onset, date of AE resolved, AE duration, severity grade, relationship to study drug, action taken, SAE). Additionally, the following variables were also listed: Serum human chorionic gonadotropin (hCG) pregnancy test, Physical examination, vital signs (pulse, blood pressure), weight (kg), height (cm), Laboratory (hematology, clinical chemistry, urinalysis) values

02

Conditions studied

  • Severe Chronic Neutropenia

Keywords

  • Filgrastim, immunogenicity, severe chronic neutropenia
03

In context

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted before Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  1. Patients with established congenital, cyclic or idiopathic severe chronic neutropenia having an indication for treatment with Sandoz' filgrastim according to the SmPC of the product
  2. Patients ≥ 18 years of age at the day of inclusion
  3. Written of patient

Exclusion criteria:.

  1. Chemotherapy-induced neutropenia
  2. Neutropenia in combination with confirmed diagnosis of disease, e.g. rheumatoid arthritis, Felty's syndrome, or systemic lupus erythematosus
  3. Myelodysplastic syndrome or leukemia
  4. Thrombocytopenia ( \< 50.000/mm3) or anemia ( \< 8 g/dl) with the exception of patients with Shwachman-Diamond syndrome, glycogen storage disease 1b, or Barth's syndrome
  5. Sickle cell disease
  6. History of of any organ system, treated or untreated, with the exception of localized basal cell carcinoma of the skin
  7. For patients with congenital severe chronic neutropenia only: Any cytogenetic aberrations in bone marrow aspirates with results not older than six months suspicious for malignant transformation.
  8. Known or suspected to rhG-CSF products
  9. Known or suspected hypersensitivity to any of the of Sandoz' filgrastim product
  10. Positive result of anti-rhG-CSF antibody assessment at screening
  11. Absolute and relative as specified in the SmPC of Sandoz' filgrastim
  12. Drug abuse, substance abuse, or alcohol abuse
  13. Use of any other drug at the time of enrollment, or within 30 days or 5 half-lives prior to enrollment, whichever is longer
  14. Patients unwilling and/or who are not capable of ensuring compliance with the provisions of the study protocol
  15. Pregnant or breastfeeding women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test
  16. Women of , defined as all women physiologically capable of becoming pregnant, UNLESS they are using a highly effective method of (i.e. one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives and intrauterine devices (IUDs)). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Zarzio®/Filgrastim HEXAL®

    Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).

    Biological: Filgrastim

Interventions

  • BiologicalFilgrastim

    Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.

    Also known as: Zarzio®/Filgrastim HEXAL®, EP2006, rhG-CSF

06

What researchers measure

Primary outcomes

  1. Incidence of Anti- Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Antibodies

    Incidence of anti-rhG-CSF antibodies was monitored. Patients were screened for anti-rhG-CSF antibodies at screening and at each study except visit 02 (start of treatment = baseline). Evaluation of immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP) and a validated cell-based neutralization antibody assay (NAB).

    Time frame: screening, 3, 6, 9 and 12 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Patients experiencing AEs by system organ class and preferred term (PT) and number of events. Patients with more than one AE coded to the same PT were counted once per PT

    Time frame: 12 months

  2. Change in Absolute Neutrophile Count (ANC)

    To evaluate the efficacy of Zarzio®/Filgrastim HEXAL® in patients with SCN in terms of changes in absolute neutrophile count (ANC). Change from each visit to baseline in ANC for all patients is calculated.

    Time frame: Participants were followed for a duration of 12 months and ANC was assessed at baseline, week 6, Month 3, Month 6, Month 9 and Month 12.

07

Results

Posted Mar 28, 2016
Limitations and caveats
This was an Additional Pharmacovigilance Activity (MEA005). Based on interim study data, complemented with clinical data from continued global development \& extensive post-marketing experience MEA005 was considered fulfilled and the study terminated.

Participant flow

First patient in: 05-Jul-2011, last patient in: 12-Feb-2013. 2 sites (medical school and university hospital)

Participant flow — Overall Study
MilestoneZarzio®/Filgrastim HEXAL® (EP2006)
Started6
Completed6
Not completed0

Outcome measures

PrimaryIncidence of Anti- Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Antibodies

Incidence of anti-rhG-CSF antibodies was monitored. Patients were screened for anti-rhG-CSF antibodies at screening and at each study except visit 02 (start of treatment = baseline). Evaluation of immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP) and a validated cell-based neutralization antibody assay (NAB).

Time frame:
screening, 3, 6, 9 and 12 months
Reported as:
Number · participants
Incidence of Anti- Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Antibodies
participantsZarzio®/Filgrastim HEXAL®
Visit 1 - negative6
Visit 3 - negative5
Visit 4 - negative6
Visit 5 - negative6
Visit 6 - negative6
Visit 7 - negative6
SecondaryNumber of Participants With Adverse Events (AEs)

Patients experiencing AEs by system organ class and preferred term (PT) and number of events. Patients with more than one AE coded to the same PT were counted once per PT

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsZarzio®/Filgrastim HEXAL®
Number of Participants With Adverse Events (AEs)6
SecondaryChange in Absolute Neutrophile Count (ANC)

To evaluate the efficacy of Zarzio®/Filgrastim HEXAL® in patients with SCN in terms of changes in absolute neutrophile count (ANC). Change from each visit to baseline in ANC for all patients is calculated.

Time frame:
Participants were followed for a duration of 12 months and ANC was assessed at baseline, week 6, Month 3, Month 6, Month 9 and Month 12.
Reported as:
Median · 10^9 cells/L
Change in Absolute Neutrophile Count (ANC)
10^9 cells/LZarzio®/Filgrastim HEXAL®
ANC Visit 1 Screening to Baseline (Visit 2)-1.252 (-10.90 to 2.84)
ANC Visit 3 Week 6 to Baseline (Visit 2)6.873 (-11.20 to 16.40)
ANC Visit 4 Month 3 to Baseline (Visit 2)-0.198 (-11.00 to 25.50)
ANC Visit 5 Month 6 to Baseline (Visit 2)-0.711 (-10.80 to 12.38)
ANC Visit 6 Month 9 to Baseline (Visit 2)1.506 (-9.60 to 14.70)
ANC Visit 7 Month 12 to Baseline (Visit 2)1.579 (-10.80 to 18.87)

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Zarzio®/Filgrastim HEXAL®—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventOpen-label Zarzio®/Filgrastim HEXAL®
NephrolithiasisRenal and urinary disorders1/6
Most frequent other events
Showing 10 of 27
Most frequent other events
EventOpen-label Zarzio®/Filgrastim HEXAL®
NasopharyngitisInfections and infestations3/6
HeadacheNervous system disorders3/6
FatigueGeneral disorders2/6
Genital infection fugalInfections and infestations1/6
GingivitisInfections and infestations1/6
Groin abscessInfections and infestations1/6
Herpes virus infectionInfections and infestations1/6
Mucosal infectionInfections and infestations1/6
Oral herpesInfections and infestations1/6
PneumoniaInfections and infestations1/6

Baseline characteristics

Intent-to treat (ITT): All patients with at least one dose EP2006. Safety population (SAF): ITT and at least one post-baseline safety assessment. Immunogenicity population: ITT and at least one available anti-rhG-CSF antibody assessment. No patient was excluded of any of the populations. Results presented for SAF.

Age, Continuous
Age, Continuous(years)Zarzio®/Filgrastim HEXAL®
Median45.0 (27 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Zarzio®/Filgrastim HEXAL®
Female5
Male1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Zarzio®/Filgrastim HEXAL®
Caucasian5
Latin American1
Region of Enrollment
Region of Enrollment(participants)Zarzio®/Filgrastim HEXAL®
Sweden4
Germany2
Severe Chronic Neutropenia (SCN) diagnosis
Severe Chronic Neutropenia (SCN) diagnosis(participants)Zarzio®/Filgrastim HEXAL®
Congenital neutropenia1
Cyclic neutropenia1
Idiopathic neutropenia4
Granulocyte Colony Stimulating Factor (G-CSF) pretreatment
Granulocyte Colony Stimulating Factor (G-CSF) pretreatment(participants)Zarzio®/Filgrastim HEXAL®
Yes6
No0
Height
Height(cm)Zarzio®/Filgrastim HEXAL®
Median165.0 (159 to 174)
Weight
Weight(kg)Zarzio®/Filgrastim HEXAL®
Median67.0 (55 to 98)
08

Study locations

2 sites
  • Medizinischen Hochschule (MHH) Hannover
    Hannover, Germany
  • Karolinska Institut
    Stockholm, Sweden
09

References and documents

Publications

  • Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Freedman MH, Kannourakis G, Kinsey SE, Davis R, Scarlata D, Schwinzer B, Zeidler C, Welte K. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003 Feb;72(2):82-93. doi: 10.1002/ajh.10255. PubMed 12555210 ↗
  • Palmblad J, Papadaki HA. Chronic idiopathic neutropenias and severe congenital neutropenia. Curr Opin Hematol. 2008 Jan;15(1):8-14. doi: 10.1097/MOH.0b013e3282f172d3. PubMed 18043240 ↗
  • Zeidler C, Welte K. Hematopoietic growth factors for the treatment of inherited cytopenias. Semin Hematol. 2007 Jul;44(3):133-7. doi: 10.1053/j.seminhematol.2007.04.003. PubMed 17631177 ↗

Individual participant data

Plan to share: Yes — Since there are only six patients enrolled, all the patient data is already provided in the registry.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2013
First posted
May 22, 2013
Start
Jul 2011
Primary completionActual
Mar 2014
CompletionActual
Sep 2015
Results first posted
Mar 28, 2016
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01859637
Lead sponsor
Sandoz
Collaborators
Sandoz GmbH
Responsible party
Sponsor
First posted
May 22, 2013
Start date
Jul 2011
Primary completion
Mar 2014
Completion
Sep 2015
Results posted
Mar 28, 2016
Last update
Mar 28, 2016

Study contacts

Roumen Nakov, MD, PhD
study director · Sandoz Biopharmaceutical, Hexal AG, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion